摘要
目的:评价蔡氏内异系列方治疗子宫内膜异位症(EM)伴有疼痛的临床优势。方法:采用非随机同期对照研究的方法与西药孕三烯酮作对照,将痛经症状评分、中医症状积分等作为疗效判定指标,同时观察该系列方对前列腺素F1α(PGF1α)、血栓素B2(TXB2)的改善作用,初步探讨其作用机制。结果:临床观察74例EM合并痛经患者,治疗组40例,总有效率为92.5%;对照组34例,总有效率为88.2%;两组疗效相比差异无统计学意义。但内异系列方在改善中医证候方面疗效优于西药对照组,且能显著降低PGF1α、TXB2的水平(P<0.05)。结论:内异系列方对子宫内膜异位症伴有疼痛的患者具有明显的临床优势。内异系列方能有效改善EM的痛经症状及中医证候积分,其初步作用机制可能与改善前列腺素F1α和血栓素B2水平有关。
Objective：To evaluate the clinical curative effect of Neiyi Xilie （NYXL） decoction of Cai which treats EM patients with dysmenorrhea syndrome.Methods：Applied the non-randomly comparative method to compare the effectiveness of Neiyi Xilie decoction with the western medicine-Gestrinone treatment.It used the patients＇ ache integral,the TCM cor relative symptom integral,as effective treatment indicators.In the mean time,the study observed treatment progress when using Neiyi Xilie decoction toward PGF1α and TXB2 to briefly explore its function mechanism.Results：Clinically observed 74 patients with dysmenorrhea syndrome.Forty of them were in the treatment group.The total effective rate was 92.5%.The control group size was 34.Its total effective rate was 88.2%.There was no statistical significance between the two groups.This study concluded that Neiyi Xilie decoction was better than the control group in area of the TCM correlative symptom.The Neiyi Xilie decoction decreased the level of PGF1α and TXB2 significantly （P0.05）.Conclusion：To summarize,it is significant for the clinical curative effect of Neiyi Xilie decoction to treat EM patients with dysmenorrhea syn drome.The Neiyi Xilie decoction can effectively reduce the pain of EM patients with dysmenorrheal and decrease the TCM correlative symptom integral.Its initial function mechanism may be related with the level of PGF1α and TXB2.
出处
《中国当代医药》
2010年第29期4-6,共3页
China Modern Medicine
基金
上海市卫生局课题(2006T003A)
